abstract |
Embodiments of the disclosure concern cell therapy methods and compositions utilizing cells expressing at least a chimeric TGFβ receptor including the exodomain of a TGFβII receptor and an endodomain that is not from TGFβ receptor, thereby converting the negative signal of TGFβ for T cell proliferation into a T cell activation signal. In at least certain aspects, cells harboring the chimeric TGFβ receptor also harbor one or more chimeric antigen receptors. |